Can a memory pill combo shield your brain from radiation?
NCT ID NCT07470606
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether taking memantine (a memory drug) plus raloxifene (a bone drug) can help prevent memory loss in adults receiving radiation for brain tumors. About 108 participants will be followed with MRI scans to see if their brain's memory center stays healthier. The goal is to find a way to preserve thinking skills during cancer treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Memantine and raloxifene
- What this could lead to
- If successful, this could offer a way to protect memory and thinking skills in people undergoing brain radiation for cancer.
- What could go wrong
- This is an early phase 2 trial with only 108 participants, so results may not apply to everyone. The drugs may cause side effects or fail to show benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mays Cancer Center, UT Health San Antonio
San Antonio, Texas, 78229, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can trained immune cells outsmart brain tumors?
- Digital tests may offer a new way to track brain health in tumor patients
- Mapping the hidden toll of brain radiation on young minds
- Scientists create detailed brain maps to protect language during surgery
- Could a cancer drug shrink recurrent brain tumors?
- Engineered immune cells target deadly brain tumors in children